Esbriet (pirfenidone) is an oral pyridone medication indicated for treating idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring and thickening of lung tissue. This TGF-beta synthesis inhibitor slows the progression of IPF by interfering with the formation of scar tissue in the lungs. For patients seeking specialized respiratory medications, working with pulmonologists ensures proper monitoring and management, as Esbriet requires careful medical supervision due to potential serious side effects including liver injury, photosensitivity reactions, and gastrointestinal complications that necessitate regular monitoring and dose adjustments for safe long-term treatment.